Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Robert Niven (Manchester, United Kingdom), Rob Niven. APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma. Eur Respir J 2015; 46: Suppl. 59, 4013

Member's Comments

No comment yet.

Related content which might interest you: The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta Source: International Congress 2016 – Asthma management Year: 2016 First clinical trial of a new IgE-adsorber in allergic asthma Source: International Congress 2015 – Novel mechanisms and treatments in allergy and asthma Year: 2015 Long-term using of omalizumab in children with atopic severe persistent non-controlled asthma Source: Annual Congress 2013 –Uncontrolled and severe asthma in children Year: 2013 Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study Source: International Congress 2016 – Asthma points to ponder Year: 2016 Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Interim analysis of a prospective study investigating oral corticosteroid (OCS) use in omalizumab treated severe allergic asthma patients: APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Should patients with mild asthma be excluded from allergic rhinitis drug trials? Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Combined therapy of asthma and allergic rhinitis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study Source: International Congress 2017 – Asthma management Year: 2017 Patients with allergic and eosinophilic asthma in the German severe asthma registry Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014